Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAPEO.L Regulatory News (APEO)

  • There is currently no data for APEO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Estimated NAV at 29 February 2024

19 Mar 2024 07:00

RNS Number : 3068H
abrdn Private Equity Opp Trst plc
19 March 2024
 

abrdn Private Equity Opportunities Trust plc

Legal Entity Identifier (LEI): 2138004MK7VPTZ99EV13

 

19 March 2024

abrdn Private Equity Opportunities Trust plc ("APEO" or "the Company") announces its estimated net asset value ("NAV") at 29 February 2024

· Estimated NAV at 29 February 2024 was 764.8 pence per share (estimated NAV at 31 January 2024 was 748.6 pence per share)

· Excluding new investments, 65.8% by value of portfolio dated 31 December 2023 (estimated NAV at 31 January 2024 was 99.6% dated 30 September 2023)

· APEO paid £18.4 million of drawdowns to fund commitments and co-investments, and received £4.1 million of distributions from fund investments during the month of February

· One new primary investment and one follow-on investment into an existing co-investment was made during February

· Outstanding commitments of £673.2 million at 29 February 2024

· Liquid resources (cash balances plus undrawn credit facilities) were £203.3 million as at 29 February 2024

 

APEO's valuation policy for private equity funds and co-investments is based on the latest valuations reported by the managers of the funds and co-investments in which the Company has interests. In the case of APEO's valuation at 29 February 2024, excluding new investments, 65.8% by value of the portfolio valuations were dated 31 December 2023. The value of the these investments is therefore calculated as the 31 December 2023 valuation, adjusted for subsequent cashflows over the period to 29 February 2024.

Of the remaining portfolio, 34.0% by value of the portfolio valuations excluding new investments, were dated 30 September 2023. The value of these investments is calculated as the 30 September 2023 valuation, adjusted for subsequent cashflows over the period to 29 February 2024. This is an update from the estimated NAV at 31 January 2024, whereby 99.6% of the portfolio valuations, excluding new investments, were dated 30 September 2023, adjusted for subsequent cashflows over the period to 31 January 2024.

 

Estimated NAV

At 29 February 2024, APEO's estimated NAV was 764.8 pence per share (estimated net assets £1,173.1 million), representing a 2.2% per share increase from the estimated NAV at 31 January 2024 of 748.6 pence per share (estimated net assets £1,151.0 million). The 16.2 pence increase in NAV per share reflected gains arising primarily from a 1.9% constant currency uplift in the valuation of investments as at 31 December 2023 received to date and a 0.3% appreciation in the euro versus sterling during February. The NAV accretion also includes the effects of the Company's share buy-back program announced in January 2024 which is currently in effect.

The 1.9% constant currency quarterly uplift in the valuation of investments received to date from the reported estimated NAV at 31 December 2023 was due to a broad increase across the portfolio. APEO's primary fund, secondary and co-investment portfolios increased 2.0%, 1.3% and 1.8% in constant currency respectively over the quarter.

 

Drawdowns and distributions

APEO paid £6.8 million of drawdowns to fund commitments and received £4.1 million of distributions from fund investments during the month of February. Including the funding of co-investments committed to during January and February, total net outflows from investment activity in February amounted to £14.3 million.

Drawdowns during the period were across several of APEO's fund investments, primarily to fund new underlying portfolio company investments and management fees.

The distributions received generated realised gains and income of £2.7 million and largely related to realisations in APEO's underlying portfolio of companies. The main realisation during the month related to the sale of KeHE Distributors (distributors of organic food products) by Towerbrook Investors IV.

 

Investment activity

A new primary commitment of ?15.0 million was made to Altor Climate Transition Fund, a fund focused on decarbonising hard to abate industries across Northern Europe.

A follow-on commitment of $1.0 million has been to a US-headquartered consumer business alongside one of the Company's core private equity managers, the details of which remain undisclosed due to confidentiality restrictions. This follow-on commitment is subsequent to an initial investment of $5.0 million in December 2022.

 

Commitments

The Company had £673.2 million of outstanding commitments at 29 February 2024. The Manager believes that around £91.6 million of the Company's existing outstanding commitments are unlikely to be drawn.

 

Credit facility and cash balances

The Company has a £300.0 million syndicated revolving credit facility provided by The Royal Bank of Scotland International Limited, Societe Generale and State Street Bank International GmbH, and it expires in December 2025. The Company drew a total of £17.1 million from the facility during the month of February, increasing the total drawn balance to £111.2 million at 29 February 2024. The remaining undrawn balance of the facility at 29 February 2024 was therefore £188.8 million.

In addition, the Company had cash balances of £14.5 million at 29 February 2024. Liquid resources, calculated as the total of cash balances and the undrawn balance of the credit facility, were therefore £203.3 million as at 29 February 2024.

 

Future announcements

The Company is expecting to announce its estimated NAV at 31 March 2024 on or around 15 April 2024.

Additional detail about APEO's NAV and investment diversification can be found on APEO's website. Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website is incorporated into, or forms part of, this announcement.

 

For further information please contact Alan Gauld at abrdn Capital Partners LLP (0131 528 4424)

Notes:-

abrdn Private Equity Opportunities Trust plc is an investment company managed by abrdn Capital Partners LLP, the ordinary shares of which are admitted to listing by the UK Listing Authority and to trading on the Stock Exchange and which seeks to conduct its affairs so as to qualify as an investment trust under sections 1158-1165 of the Corporation Tax Act 2010.

The Company intends to release regular estimated NAV updates around ten business days after each month end. A breakdown of APEO's portfolio can be obtained in the latest monthly factsheet, which is published on APEO's website at:

www.abrdnpeot.co.uk

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NAVEAXDPFAFLEFA
Date   Source Headline
9th Jun 20237:00 amRNSNotice of Results
17th May 202311:51 amRNSHolding(s) in Company
17th May 20237:00 amRNSEstimate NAV at 30 April 2023
25th Apr 202311:52 amRNSDirector/PDMR Shareholding
18th Apr 20237:00 amRNSEstimated NAV at 31 March 2023
11th Apr 202311:23 amRNSQuarterly disclosure
22nd Mar 20231:41 pmRNSResult of AGM
16th Mar 20237:00 amRNSEstimated NAV at 28 February 2023
9th Mar 20237:00 amRNSFirst Interim Dividend
14th Feb 20237:00 amRNSEstimated NAV at 31 January 2023
10th Feb 20238:57 amRNSDoc re. Annual Financial Report
9th Feb 20234:40 pmRNSSecond Price Monitoring Extn
9th Feb 20234:35 pmRNSPrice Monitoring Extension
31st Jan 202311:38 amRNSDirector/PDMR Shareholding
31st Jan 202310:49 amRNSAnnual Financial Report
31st Jan 20237:00 amRNSAnnual Financial Report
18th Jan 20232:10 pmRNSNotice of Results
18th Jan 20237:00 amRNSEstimated NAV at 31 December 2022
9th Jan 20238:51 amRNSQuarterly disclosure
15th Dec 20227:00 amRNSEstimated NAV at 30 November 2022
13th Dec 20223:18 pmRNSFourth Interim Dividend Announcement
28th Nov 20227:01 amRNSCompany Secretary - Change of Name
21st Nov 20224:36 pmRNSPrice Monitoring Extension
14th Nov 20227:00 amRNSEstimated NAV at 31 October 2022
2nd Nov 20222:13 pmRNSDirector/PDMR Shareholding
1st Nov 20224:41 pmRNSSecond Price Monitoring Extn
1st Nov 20224:36 pmRNSPrice Monitoring Extension
28th Oct 20229:42 amRNSEdison update on abrdn Private Equity Opp Trst
24th Oct 20224:41 pmRNSSecond Price Monitoring Extn
24th Oct 20224:36 pmRNSPrice Monitoring Extension
14th Oct 20227:00 amRNSEstimated NAV at 30 September 2022
10th Oct 20227:00 amRNSIncrease of Loan Facility
7th Oct 202210:33 amRNSQuarterly disclosure
16th Sep 20224:35 pmRNSPrice Monitoring Extension
15th Sep 20227:00 amRNSEstimated NAV at 31 August 2022
9th Sep 20224:36 pmRNSPrice Monitoring Extension
8th Sep 20224:36 pmRNSResearch from QuotedData
8th Sep 202211:21 amRNSDirector/PDMR Shareholding
8th Sep 202210:11 amRNSDirector/PDMR Shareholding
8th Sep 20227:00 amRNSThird Interim Dividend
12th Aug 20227:00 amRNSEstimated NAV at 31 July 2022
10th Aug 20225:49 pmRNSDirector/PDMR Shareholding
9th Aug 20227:00 amRNSEdison issues review on Abrdn Private Equity Opp.
21st Jul 20224:35 pmRNSPrice Monitoring Extension
14th Jul 202210:26 amRNSDoc re. Half Yearly Report
14th Jul 20227:00 amRNSEstimated NAV at 30 June 2022
5th Jul 20222:18 pmRNSQuarterly disclosure
30th Jun 20224:36 pmRNSPrice Monitoring Extension
30th Jun 20227:00 amRNSHalf-year Report
16th Jun 20227:00 amRNSEstimated NAV at 31 May 2022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.